Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group a, c, w-135, and y conjugate vaccine + diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, and haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK134612 + Infanrix hexa refers to the co-administration of GlaxoSmithKline's investigational tetravalent meningococcal serogroups A, C, W-135, and Y-tetanus toxoid conjugate vaccine (GSK134612, later branded as Nimenrix) with the licensed hexavalent vaccine Infanrix hexa. GSK134612 is a conjugate vaccine targeting *Neisseria meningitidis* bacteria using capsular polysaccharides from four serogroups conjugated to a tetanus toxoid carrier protein. Infanrix hexa is a combined vaccine providing protection against diphtheria, tetanus, pertussis (acellular), hepatitis B (rDNA), poliomyelitis (inactivated), and *Haemophilus influenzae* type b. Clinical trials evaluated the safety and immunogenicity of giving these two vaccines concurrently to infants and toddlers aged 12-23 months, demonstrating that co-administration does not interfere with the immune response or safety profile of either vaccine compared to separate administration.
- Other names
- GSK134612 + Infanrix hexaMenACWY-TT + DTPa-HBV-IPV/Hib
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Poliovirus type 1 capsid proteinGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)WPV3 (Poliovirus type 3 capsid protein)FHA (Filamentous hemagglutinin)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)PRN (Pertactin)HBsAg (Hepatitis B surface antigen)PRP (Haemophilus influenzae type b polyribosylribitol phosphate capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal group a, c, w-135, and y conjugate vaccine + diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, and haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group a, c, w-135, and y conjugate vaccine + diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, and haemophilus influenzae type b vaccine.